An immunohistochemical marker for Wallerian degeneration of fibers in the central and peripheral nervous system.
This work was prompted by the accidental observation that a newly developed, affinity purified polyclonal antibody against the C-terminus of the neuropeptide tyrosine (NPY) Y1-receptor protein decorates degenerating fibers in the central nervous system (CNS). This staining did not appear in control animals in which the antibody marked perikarya and dendrites at previously described locations [X. Zhang, L. Bao, Z.-Q. Xu, J. Kopp, U. Arvidsson, R. Elde, T. Hökfelt, Localization of neuropeptide Y Y1-receptors in the rat nervous system with special reference to somatic receptors on small dorsal root ganglion neurons, Proc. Natl. Acad. Sci. USA 91 (1994) 11738-11742]. Three models of experimental lesions were studied: sciatic nerve transection, spinal cord transection and parietal cortex thermocoagulation. In each model, animals were divided in groups (n=2) and processed for indirect immunofluorescence at different time intervals up to 28 days post-lesion (PL) (see below). All three experimental lesions produced a very intense immunolabeling of fibers in the projection pathways of the lesioned structures, strongly reminding of Wallerian degeneration (WD). In the sciatic nerve, the staining first appeared on day 1 PL, was strongly increased on day 3 PL, then declined after 7 days and had almost completely disappeared after 14 days. In the CNS, the staining appeared later and was first observed on day 3 PL and remained for a longer period, thus showing different time courses in the brain and spinal cord as compared to the sciatic nerve. The labeling was completely abolished, both in the CNS and in the sciatic nerve, by pre-incubation of the Y1-R antibody with the immunogenic peptide at a dilution of 10-6 M. The appearance of the staining and its time course strongly suggest that the process was related to degenerating axons. Although the protein actually detected remains to be determined, it is suggested that the staining ability of this antibody could be used as a positive marker of axonal degeneration following experimental or naturally occurring lesions of the nervous system.
D000818:Animals; D015415:Biomarkers; D002490:Central Nervous System / Q000276:immunology / Q000293:injuries / Q000473:pathology*; D003712:Dendrites / Q000737:chemistry / Q000276:immunology / Q000473:pathology; D005455:Fluorescent Antibody Technique; D017403:In Situ Hybridization; D008297:Male; D009412:Nerve Fibers / Q000737:chemistry / Q000276:immunology / Q000473:pathology*; D009478:Neuropeptide Y / Q000032:analysis; D010296:Parietal Lobe / Q000276:immunology / Q000293:injuries / Q000473:pathology; D011712:Pyramidal Tracts / Q000276:immunology / Q000293:injuries / Q000473:pathology; D012333:RNA, Messenger / Q000032:analysis; D051381:Rats; D017207:Rats, Sprague-Dawley; D017476:Receptors, Neuropeptide Y / Q000032:analysis / Q000235:genetics; D012584:Sciatic Nerve / Q000276:immunology / Q000293:injuries / Q000473:pathology*; D013788:Thalamus / Q000276:immunology / Q000293:injuries / Q000473:pathology; D014855:Wallerian Degeneration / Q000175:diagnosis / Q000276:immunology* / Q000473:pathology*